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In view of the lifelong exposure and large patient populations involved, insulin analogs
with an increased mitogenic effect in comparison to human insulin may potentially con-
stitute a major health problem, since these analogs may possibly induce the growth of
pre-existing neoplasms. At present, the available data suggest that insulin analogs are safe.
In line with these findings, we observed that serum of diabetic patients treated with insulin
analogs, compared to that of diabetic patients treated with human insulin, did not induce an
increased phosphorylation of tyrosine residues of the insulin-like growth factor-I receptor
(IGF-IR). However, the classical model of the IGF-IR signaling may be insufficient to explain
(all) mitogenic effects of insulin analogs since also non-canonical signaling pathways of the
IGF-IR may play a major role in this respect. Although phosphorylation of tyrosine residues
of the IGF-IR is generally considered to be the initial activation step within the intracellular
IGF-IR signaling pathway, it has been found that cells undergo a signaling switch under
hyperglycemic conditions. After this switch, a completely different mechanism is utilized
to activate the mitogenic (mitogen-activated protein kinase) pathways of the IGF-IR that is
independent from tyrosine phosphorylation of the IGF-IR. At present it is unknown whether
activation of this alternative intracellular pathway of the IGF-IR occurs during hyperglycemia
in vivo and whether it is stronger in patients treated with (some) insulin analogs than in
patients treated with human insulin. In addition, it is unknown whether the insulin receptors
(IRs) also undergo a signaling switch during hyperglycemia. This should be investigated in
future studies. Finally, relative overexpression of IR isoform A (IR-A) in (pre) cancer tissues
may play a key role in the development and progression of human cancers during treatment
with insulin (analogs). Further studies are required to unravel whether the IR-A is involved
in the development of cancers and whether, in this respect (some) insulin analogs differ
from human insulin.
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INTRODUCTION
Insulin analogs have been developed in an attempt to achieve a
more physiological replacement therapy of insulin, thereby achiev-
ing a better glycemic control. However, structural modifications
of the insulin molecule may also result in altered binding affinities
and activities to the insulin-like growth factor-I receptor (IGF-
IR). As a consequence, insulin analogs may (theoretically) have an
increased mitogenic action compared to human insulin. In view
of the lifelong exposure and large patient populations involved,
insulin analogs with increased mitogenic effects in comparison to
human insulin may constitute a major health problem, since these
analogs could induce the growth of pre-existing neoplasms.
In 2009, several large observational studies suggested that use of
insulin analogs and especially the use of insulin glargine was asso-
ciated with an increased risk of cancer (1–4). The American Food
and Drug Agency (FDA) concluded that the evidence presented
was inconclusive due to the limitations in how these studies
were designed, carried out, and in the data available for analysis
[Early Communication about Safety of Lantus (insulin glargine);
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety
InformationforPatientsandProviders/DrugSafetyInformation
forHeathcareProfessionals/ucm169722.htm]. Nevertheless these
findings did raise concerns as to whether or not insulin analogs
promote cell proliferation and growth of (subclinical) neoplasms.
STRUCTURAL AND FUNCTIONAL OVERLAP BETWEEN
INSULIN AND INSULIN-LIKE GROWTH FACTOR-I
Very early in the evolution insulin and IGF-I emerged from a
common molecule called proto-insulin (5). As a consequence of
this common background there is a high homology in the mol-
ecular structure between insulin and IGF-I (5, 6). As insulin and
IGF-I probably arose during evolution by gene duplication, there
is the hypothesis that the insulin receptor (IR) and IGF-IR were
also created by gene duplication of a common precursor recep-
tor molecule (7). Due to the common evolutionary background,
the molecular structure of the IR and the IGF-IR probably show
high homology (7). Both consist out of two alpha subunits and
two beta subunits, which are connected by disulfide bounds. Both
receptors contain tyrosine kinase domains. Against their common
background, it may not seem unexpected that both the IR and the
IGF-IR share intracellular signaling pathways, which are involved
in mitogenic and metabolic actions (8). Both insulin and IGF-
I stimulate cell proliferation increasing DNA and RNA synthesis
and by inhibiting apoptosis (9). In addition, both insulin and IGF-I
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effectuate metabolic effects, stimulate glucose uptake and protein
synthesis, and inhibit breakdown of fat (9). Binding of human
insulin to the IR primarily influences metabolic effects, although
in some circumstances and in some cells it also induces growth
promoting effects (10). In contrast, binding of IGF-I to the IGF-
IR, primarily stimulates cell growth, but in some circumstances
and in some cells, also stimulates metabolic effects (10).
In vitro, it has been found that insulin binds to the IGF-IR with
low affinity and IGF-I binds to the IR with low affinity (10). How-
ever, the question remains whether this latter phenomenon also
occurs in vivo.
It is thought that in vivo stimulating effects of human insulin
on the IR normally dominate over that on the IGF-IR (Figure 1).
ARE STIMULATING EFFECTS OF INSULIN ANALOGS TO THE
INSULIN RECEPTOR AND THE IGF-I RECEPTOR COMPARABLE
TO HUMAN INSULIN?
How does stimulation of the IR by insulin analogs compare to
stimulation of the IGF-IR in vivo? Does, like human insulin,
IR stimulation dominate over IGF-IR stimulation (Figure 2A)?
Or, alternatively and in contrast to human insulin, does IGF-IR
stimulation dominate over IR stimulation (Figure 2B)?
Currently, there are three rapid-acting insulin analogs (insulin
lispro, insulin aspart, and insulin glulisine) and three long-acting
insulin analogs (insulin glargine, insulin detemir, and insulin
degludec) commercially available. For insulin glargine (11), a
slightly lower affinity for the IR but a significant higher affinity
for the IGF-IR has been reported. For insulin aspart, the affinity
for the IR and the IGF-IR have been reported to be similar to
that of human insulin (12, 13). For insulin glulisine, compared
to human insulin, a similar or even slightly less binding affin-
ity for the IR has been found, while the IGF-IR binding affinity
has been reported to be significantly lower than that of human
insulin (14). In vitro studies show decreased IR binding affinity
for insulin glargine compared to human insulin while the IGF-IR
binding affinity in vitro has been reported to be stronger for insulin
FIGURE 1 | Overall effects of human insulin on the insulin receptor
dominate over that on the IGF-I receptor.
glargine than for human insulin (12, 15). For insulin detemir, com-
pared to human insulin, the affinity for the IR in vitro has been
found to be reduced, while the IGF-IR binding affinity has been
reported to be significantly reduced as well as increased (11, 16).
To date information on insulin degludec is limited. It has been
reported that IR binding of insulin degludec is comparable to
human insulin in vitro, while its affinity for the IGF-IR is low (17).
Thus, in vitro, all at present commercially available insulin
analogs have equal or lower affinities for the IR than human
insulin suggesting no important role of the IR in mitogenesis.
At the same time, it has been suggested that especially insulin
analogs with an increased affinity for the IGF-IR are more mito-
genic than human insulin (13). In accordance with these data,
cell models that permit comparisons of the activity of insulin
to that of insulin analogs indicate that only minor differences
exist between insulin and short-acting analogs (16). By contrast,
some long-acting analogs activate the mitogenic signaling pathway
more effectively than insulin and cause increased cell prolifera-
tion (16). However, the biological response of a target cell is not
FIGURE 2 |What is the balance of effects of insulin analogs on the
insulin receptor compared to the IGF-I receptor? Do stimulating effects
of insulin analogs on the insulin receptor dominate over the stimulating
effects on the IGF-I receptor (like human insulin) (A)? Or, do stimulating
effects of insulin analogs on the IGF-I receptor (in contrast to human insulin)
dominate over stimulating effects of insulin analogs on the insulin
receptor (B)?
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only determined by the affinity of the insulin analog–receptor
interaction, but also by a number of other factors such as the
concentration of receptors on the target cells and the concentra-
tion of an insulin analog. Interestingly, it has been reported that
in vivo during treatment with insulin detemir and the recently
introduced insulin degludec, relatively high circulating concen-
trations are achieved (18). Although a large fraction of these two
insulins is bound to albumin, there is yet no clear information on
the plasma concentrations of the free moiety for these two insulin
preparations (18).
EFFECTS OF INSULIN ANALOGS ASSESSED BY THE IGF-I
KINASE RECEPTOR ACTIVATION ASSAY
In order to gain more insight into the possible growth promoting
effects of insulin analogs, we have used the so-called IGF-I kinase
receptor activation (KIRA) assay. The IGF-I-KIRA assay uses a
human embryonic kidney cell line (293 EBNA) highly transfected
with cDNA encoding the full-length of the IGF-IR gene (19). The
IGF-I KIRA assay is capable of quantifying IGF-I bioactivity by
measuring IGF-I-induced receptor-phosphorylation after binding
of IGF-I or other ligands to the IGF-IR (19). As above discussed
the IGF-IR contains two alpha subunits, two beta subunits, which
contain both a so called tyrosine kinase domain. Binding of IGF-I
or another ligand to the IGF-IR causes phosphorylation of tyro-
sine residues in the beta units, which is generally considered to be
the initial step in activation of the intracellular IGF-IR signaling
pathway. This first step of intracellular signaling can be quantified
in a time resolved fluorometer [for more details of this method see
Ref. (20)].
By using the IGF-I KIRA assay, we compared IGF-IR activa-
tion in vitro induced by human insulin, two short-acting insulin
analogs (insulin aspart and insulin lispro) and two long-acting
insulin analogs (insulin glargine and insulin detemir). Overall,
short-acting insulin analogs did not differ substantially in acti-
vating the IGF-IR from human insulin. Insulin lispro was slightly
more potent in activating the IGF-IR than human insulin and
insulin aspart, only reaching statistical significance at 100 nM
(21). The two long-acting insulin analogs differed substantially
from each other in activating the IGF-IR. At concentrations above
1 nmol/L, insulin glargine was more potent in IGF-IR activa-
tion than human insulin and insulin detemir (21). However,
at more physiological concentrations (i.e., below concentrations
of 1 nmol/L), no differences in IGF-IR activation were observed
between insulin glargine, human insulin, and insulin detemir (21).
The IGF-IR activation induced by insulin glargine was significantly
lower compared to pure IGF-I over the whole range of concen-
trations tested. Thus our in vitro experiments showed that insulin
glargine was able to activate the IGF-IR more strongly than human
insulin and insulin detemir, yet still significantly less strong than
IGF-I.
By using the same IGF-I KIRA assay in another in vitro experi-
ment, we compared IGF-IR activation induced by insulin glargine
and insulin NPH. Insulin glargine was more potent in IGF-IR
activation than NPH insulin at 10–100 nmol/L (22). Again we
found no differences in IGF-IR activation between insulin glargine
and NPH insulin at more physiological concentrations (i.e., below
concentrations of 1 nmol/L) (22).
Next we studied serum samples of 104 patients with type 2
diabetes from the LANMET study (23). In the LANMET study,
diabetic subjects, who were poorly controlled under metformin
monotherapy, were randomized to receive either metformin with
insulin glargine or metformin with NPH insulin (23). We mea-
sured IGF-I bioactivity with the IGF-IR KIRA assay in fasting
samples at two time points: at baseline and after 36 weeks of
combined metformin and insulin therapy. Importantly, in the
36 weeks of follow-up metabolic control improved and overall
HbA1c decreased from 75 to 53 mmol/mol (9–7%). IGF-I bioac-
tivity significantly decreased after 36 weeks of treatment and was
slightly lower than a non-diabetic control group (22). In this
respect, there were no differences in circulating IGF-I bioactiv-
ity and metabolic control between subjects treated with insulin
glargine and subjects treated with NPH (22).
HOW TO EXPLAIN THE DISCREPANCY BETWEEN THE
IN VITRO AND VIVO RESULTS WITH THE IGF-I KIRA ASSAY?
As discussed above, the in vitro findings leading to the hypoth-
esis of an increased growth promoting activity on the IGF-IR
by insulin glargine could not be supported by our in vivo data.
What could explain the observed differences in IGF-I bioactivity
after administration of insulin glargine during in vitro and in vivo
conditions?
There are at least three not mutually exclusive explanations for
our findings:
(1) In vivo insulin glargine did not reach concentrations at which
we and others have observed differences in IGF-IR activation
in vitro compared to human insulin.
(2) It should be stressed that in the LANMET study all sub-
jects were treated with metformin. Metformin appears to
have pleiotropic mechanisms of action, including increasing
peripheral insulin sensitivity (24). Since an inverse relation-
ship between insulin sensitivity and circulating IGF-I bioactiv-
ity has been found (25–27), the metformin-induced increase
in peripheral insulin sensitivity may have contributed to the
observed lower circulating IGF-I bioactivity during insulin
glargine treatment.
(3) Furthermore, after subcutaneous injection, insulin glargine
is partially degraded into two bioactive products (M1 and
M2) (28). After 36 weeks of insulin glargine treatment, we
found that plasma M1 concentrations had increased from
undetectable to 1.5 ng/mL, while insulin glargine itself and
M2, the other metabolite of insulin glargine, remained unde-
tectable (29). The M1 degradation product has previously
been shown to have considerable less mitogenic potency than
insulin glargine itself (28). In line with this finding, we found
that, in vitro, compared to NPH insulin, M1 activated the
IGF-IR similarly (29).
Recently, the prospective ORIGIN trial provided evidence that
low dose insulin glarigine (median 0.40 units/kg), when used to
target normal fasting plasma glucose levels for more than 6 years,
had a neutral effect on the development of cancers (30). Thus
all these data are reassuring and suggest that insulin glargine
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compared to human insulin (at least in low doses) does not
increase IGF-IR signaling in vivo.
Nevertheless, in our opinion the debate about long-term safety
of insulin analogs is still not closed. Like all in vitro systems, the
IGF-I KIRA assay does not mimic the exact in vivo conditions.
Vigneri et al. have suggested that long-acting insulin analogs have
a prevalent activation of the extracellular regulated kinase (ERK)
pathway (the mitogenic pathway) rather than the AKT pathway
(which is considered the metabolic pathway) (13). Although with
the IGF-I KIRA assay, phosphorylation of the tyrosine residues
within the ß-subunits of the IGF-IR is quantified, it cannot be
assessed whether or not activation in vivo of the IGF-IR by an
insulin analog results (like human insulin) in a balanced metabolic
and mitogenic activity at cellular level.
A further important point to address is that all serum samples
of the diabetic subjects from the LANMET study were studied
with the IGF-I KIRA assay in vitro under normoglycemic condi-
tions (5.5 mmol/L). Hyperglycemia ensures a high glucose supply
for cells favoring anabolic metabolism to fuel tumor growth and
this has been suggested (at least partly) to explain the increased
cancer risk associated with diabetes (31). However, hyperglycemia
may also change IGF-IR signaling. Clemmons et al. have shown
that, under normoglycemic conditions, stimulation of the IGF-IR
expressed on vascular smooth muscle cells and vascular endothe-
lial cells only activates IRS-1 leading to stimulation of the “meta-
bolic” (phosphoinositide 3) PI-3 kinase pathway, but not to stimu-
lation of the “mitogenic” (mitogen-activated protein) MAP kinase
pathway (32) (Figure 3A). However, they also found that, follow-
ing exposure to hyperglycemia, cells undergo a signaling switch
in vitro leading to an entirely different mechanism to activate
both the “metabolic” (PI-3 kinase) and “mitogenic” (MAP) path-
ways of the IGF-IR (32). This signaling switch leads to increased
proliferation and migration.
Activation of this alternative signaling mechanism occurs in
hyperglycemic conditions independent from tyrosine phospho-
rylation of the IGF-IR: IGF-IR linked signaling occurs via its
ability to phosphorylate SH2 domain-containing protein tyrosine
phosphatase substrate-1 (SHPS-1), which results in assembly of
a SHPS-1 signaling complex which leads to both the PI-3 kinase
and MAP kinase activation (32) (Figure 3B). Thus these find-
ings show that under hyperglycemic conditions stimulation of cell
growth may occur independently from tyrosine phosphorylation of
the IGF-IR.
Clemmons et al. postulated that activation of this alterna-
tive signaling pathway is directly linked to the pathophysiologic
processes that are involved in the pathogenesis of diabetic com-
plications such as diabetic retinopathy and atherosclerosis (32).
Since cancer can be considered as a “new complication” of dia-
betes (33) while there is also a clear relationship between hyper-
glycemia and incidence of cancer in type 2 diabetes and the
metabolic syndrome (34–38), we think that this hypothesis may
be extended and that it is worthwhile to investigate whether
hyperglycemia-induced activation of this alternative intracellu-
lar pathway of the IGF-IR is also involved in the development
of cancer in diabetes. At present it is unclear whether, during
hyperglycemic conditions, activation of this alternative intracel-
lular pathway of the IGF-IR is different for (some) insulin analogs
FIGURE 3 |The IGF-I receptor signaling pathways during
normoglycemia: (A) stimulation of the IGF-I receptor leads to
phosphorylation of insulin receptor substrate-1 (IRS-1) that couples IGF-I
receptor stimulation to downstream activation of the PI-3-kinase
(“metabolic”) signaling pathway. (B) IGF-I receptor signaling pathways
during hyperglycemia: stimulation of the IGF-I receptor leads not
phosphorylation of IRS-1. Instead of this, IGF-IR linked signaling occurs via
its ability to phosphorylate SHPS-1, which results in assembly of a SHPS-1
signaling complex which leads to stimulation of both the PI-3 kinase
(“metabolic”) signaling pathway and MAP kinase (“mitogenic”) signaling
pathway [Figure modified from Clemmons et al. (32); see also text].
compared to human insulin. This should be investigated in future
studies.
Insulin-like growth factor-I receptor is traditionally described
as an ON/OFF system, with ligand stabilizing the ON state by
exclusively kinase-dependent signaling activation (39). In fact,
the IGF-I KIRA assay is based on the idea that autophosphory-
lation of tyrosine residues within the kinase domain of the IGF-IR
is the first step and essential for subsequent activation of the
intracellular signaling pathways. However, more recently it was
suggested that the IGF-IR also behaves like a functional receptor
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tyrosine kinase/G-protein related coupled receptor hybrid “bor-
rowing”components of G-protein coupled receptor signaling (39).
In addition to the above described classical kinase pathway, IGF-IR
activity and its biological effects are further controlled by a variety
of adaptor proteins/signaling proteins through IGF-IR posttrans-
lational modifications including tyrosine and serine phosphory-
lation, dephosphorylation, ubiquitination, and sumoylation (39).
In the light of the complexity of the downstream pathways acti-
vated by the IGF-IR, it is conceivable that (some) insulin analogs
may use different post-receptor signaling pathways than human
insulin.
POTENTIAL ROLE OF IR-A IN THE DEVELOPMENT OF CANCER
Mitogenic effects of insulin may also occur via increased stimu-
lation of the IR (40). In addition, Hansen et al. have shown that
increased mitogenic potency of insulin analogs may also result
from slow ligand dissociation from the IRs (40). The IR may be
produced as A or B isoforms (IR-A and IR-B, respectively) and both
forms show different biological characteristics (41, 42). The IR-B
is considered the typical insulin target tissue receptor in the mus-
cles, liver and fat cell, and mainly involved in the insulin-mediated
metabolic effects (43). The IR-A is expressed ubiquitously, but
is predominantly expressed in the central nervous system and
in hematopoietic cells (44). Interestingly, especially the IR-A is
also overexpressed in many human cancers and IR-A has stronger
mitogenic activity than the IR-B.
The IR-A has the peculiar characteristic not only to be acti-
vated by insulin but also by IGF-II, and although to a lesser extent
to IGF-I (42, 45). Very recently, an important role for the IR-A in
the development of cancer has been suggested (16). This opens
the possibility that the IR-A holds an important position in the
stimulation of cancer cell proliferation in response to insulin and
insulin analogs (42, 43). Relative IR-A and IR-B expression may
vary in a tissue-specific manner and inter-individual differences in
the levels of proteins of the IR-A and IR-B may function as a crit-
ical determinant of the mitogenic potency of insulin and insulin
analogs. In most cancer types, the IR-A/IR-B ratio is changed;
upregulation of IR-A has been reported in breast, ovarian, colon
and thyroid cancer cell lines, and human tumors (42, 43). Relative
overexpression of IR-A may play a key role in the development
and progression of human cancers after starting treatment with
insulin (analogs).
SIGNALING PATHWAYS OF THE INSULIN RECEPTORS
Stimulation of the IRs activates at least two important different
signaling pathways (one involving MAP kinases, one involving
PI-3 kinase) (42). A third pathway may be translocation of com-
plexes of insulin or insulin analogs bound the IRs to the nucleus
of the cell (45, 46). Although the role of insulin internalization
and translocation to the nucleus is still controversial, there is sub-
stantial evidence to support a role in cellular mediated responses
induced by insulin. In favor of this latter possibility many studies
indicate that nuclear translocation of various growth factors and
hormones plays an important role in cell proliferation or DNA
synthesis (46). Further studies are required to reveal which sig-
naling pathways are actually involved in the different effects and
whether in this respect (some) insulin analogs differ from human
insulin.
There is probably a considerable crosstalk between the IR-A,
IR-B, and IGF-IR mediated functions at the receptor and post-
receptor level and the final effects are due to a combination of
IGF-IR and IRs-mediated processes. It has been suggested that
the IR and IGF-IR act at identical portals to the regulation of
gene expression, with differences between insulin and IGF-I effects
due to a modulation of the signal created by the specific ligand–
receptor interactions (47). In addition, it has been also suggested
that various ligands acting through the same receptor may acti-
vate different patterns of end-point cellular effects (“differential
signaling”) (48). As a consequence, it is almost impossible in most
in vitro cell lines to study and disentangle the individual effects of
insulin and insulin analogs on the IR-isoforms.
ARE THE INSULIN ANALOG-MEDIATED EFFECTS ON THE IR-A
DIFFERENT FROM THOSE OF HUMAN INSULIN?
Due to the above discussed considerable crosstalk between the
IR-A, IR-B, and IGF-IR, there is at present only limited informa-
tion on the interaction between the insulin analogs on the two
IR-isoforms. Sciacca et al. compared several insulin analogs for
mitogenic effects in engineered cells expressing only the IR-A or
IR-B, and found that relative to human insulin, long-acting insulin
analogs like insulin glargine and insulin detemir strongly activated
the ERK pathway and cell proliferation via the IR-A (16).
In our laboratory, we have developed KIRA assays specific
for both the IR-A and the IR-B (46). Both assays are capa-
ble of quantifying IR stimulating activity by measuring induced
receptor tyrosine kinase activation in individual serum samples.
By using KIRA assays specific for the IR-A and the IR-B, we
tested (in vitro) whether short-and long-acting insulin analogs
differed from human insulin in their potency to activate the IR-
A and IR-B. In line with a previous study by Kurtzhals et al.,
we found that short-acting insulin analogs (insulin lispro and
insulin aspart) did not differ substantially from human insulin,
nor from each other in activating either receptors (15, 21). When
comparing long-acting insulin analogs with NPH insulin, we
observed that in a concentration range of 10–100 nmol/L insulin
glargine and M2 were more potent than NPH insulin in activat-
ing IR-A and IR-B while M1 activated IR-A and IR-B similarly
compared to NPH insulin (29). Thus in vitro at supraphysiolog-
ical concentrations, insulin glargine, and its metabolite M2 were
more potent in activating both IR-isoforms compared to human
insulin.
To investigate whether our in vitro results could be extrapo-
lated to the in vivo situation, we compared serum induced IR-A
and IR-B activation (by using an IR-A and IR-B specific KIRA
assay, respectively) of type 2 diabetes patients treated with rela-
tively high doses of insulin glargine or NPH insulin (29). Serum
IR-A and IR-B bioactivity did not differ between patients treated
with insulin glargine or NPH insulin (29). Our results did not sup-
port the idea that treatment with insulin glargine in type 2 diabetes
leads to a stronger stimulation of the IRs than NPH insulin.
In subjects treated with insulin glargine therapy, we also mea-
sured insulin glargine, M1, and M2 concentrations in plasma (29).
Only M1, but not insulin glargine nor M2 could be detected in the
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plasma of these subjects (29). These latter findings may explain
why we could not find differences in potency of serum to activate
the IR-A and IR-B between subjects treated with insulin glargine
or NPH insulin.
Nevertheless, we observed a positive relationship between
insulin dose and serum induced IR-A activation in both the insulin
glargine and NPH insulin treatment groups (29). This suggests
that subjects treated with relatively high doses of insulin (ana-
log) did have the strongest activation of the IR-A. At present it is
unclear whether this has any consequences in daily clinical practice
and whether subjects using relatively high daily doses of insulin
(analogs) have an increased risk to develop cancer (see below).
Appropriately designed prospective observational studies com-
paring diabetic patients treated with “low” and “high” doses of
an insulin analog may add further useful information and shed
more light onto this important issue.
IS THE RISK OF CANCER DIRECTLY RELATED TO THE DOSE OF
INSULIN (ANALOGS) AND/OR METABOLIC CONTROL?
The debate continues to the role of insulin (analogs) when
high (supraphysiological) doses of insulin (analogs) are used
in the treatment of type 2 diabetes in an attempt to achieve
normoglycemia.
It is important to realize that in routine daily clinical prac-
tice there is a considerable delay in initiation of insulin therapy
after failure of oral glucose-lowering agents in patients with type 2
diabetes (49). But, even after starting insulin (analog) treatment, a
considerable number of subjects will still not achieve target HbA1c
levels ≤7% (50). In addition, type 2 diabetes is a progressive dis-
ease characterized by worsening of glycemia even after starting
insulin (analog) treatment. As a consequence, insulin (analog)
doses usually increase over time in order to achieve good metabolic
control (51).
In addition, most commercially available insulin analogs often
show less metabolic activity than human insulin in vitro (11).
If this is translated into an in vivo situation, it is very plausible
that compared to human insulin higher doses of an insulin ana-
log are required to attain a comparable metabolic control. As a
consequence, in vivo relatively high(er) concentrations of insulin
analogs will be present in the circulation during treatment. How-
ever, relatively high(er) concentrations of an insulin analog may
not only improve metabolic control but also increase cancer risk
by dose-dependent effects on cellular differentiation, growth, and
proliferation. Thus use of insulin analogs may have dual effects
in type 2 diabetes: decreasing cancer risk by improving meta-
bolic control but simultaneously increasing cancer risk, because
of its dose-dependent effects on cell growth and proliferation (37)
(Figure 4). In this scenario, the effects of insulin analogs on cancer
risk are directly related to glucose control: subjects with poor meta-
bolic control treated with relatively high (pharmacological) doses
of an insulin analog especially run an increased risk for cancer.
As discussed above, upon exposure to hyperglycemia, cells may
also undergo a signaling switch of IGF-IR and use alternative post-
receptor signaling mechanisms (32). Whether this latter phenom-
enon also occurs for the IRs following exposure to hyperglycemia
is at present unknown and warrants further investigation.
FIGURE 4 |The use of insulin (analogs) may have dual effects in type 2
diabetes: decreasing cancer risk by improving metabolic control (left)
but simultaneously increasing cancer risk because of its
(dose-dependent) effects on cell growth and proliferation (right). In this
scenario especially subjects with poor metabolic control treated with
relatively high pharmacological doses of insulin analogs will be at an
increased risk for cancer.
In conclusion, there is a complex relationship between the
use of insulin analogs, hyperglycemia, and cancer risk. In view
of the lifelong exposure and large patient populations involved,
insulin analogs with an increased mitogenic effect may potentially
constitute a major health problem when inducing the growth of
pre-existing neoplasms. The available data so far suggest at present
that insulin analogs are safe.
Risk of cancer may be directly related to the dose of insulin
(analogs) and/or effects on metabolic control. Upon exposure to
hyperglycemia, cells may undergo a signaling switch. After this
switch, independent from tyrosine phosphorylation of the IGF-IR,
an entirely different mechanism is utilized to activate the mitogenic
(MAP) pathways of the IGF-IR. At present it is unclear whether
activation of this alternative intracellular pathway of the IGF-IR
under hyperglycemic conditions is stronger during treatment with
(some) insulin analogs compared to human insulin. In addition,
whether a similar signaling switch also occurs for the IRs under
hyperglycemic conditions is at present unclear. This should be
investigated in future studies.
Finally, a relative overexpression of IR-A in (pre) cancer tissues
may play a key role in the development and progression of cancers.
In vitro, we observed that high doses of insulin analogs/insulin did
have the strongest activation of the IR-A. However, at present it is
unclear whether this has any consequences in clinical practice or
whether insulin analogs differ from human insulin in this respect.
Well-conducted and appropriately designed prospective observa-
tional studies comparing diabetic patients treated with “low” and
“high” doses of an insulin analog should be started to shed more
light onto this important issue.
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